“The miR-AGE trial with ABX464 has been endorsed by renowned experts in France, Europe, and the U.S.,” said Philippe Pouletty, M.D., Chairman of the Board of Abivax and CEO of Truffle Capital
French regulator, ANSM, as well as Ethics Committee, CPP, have cleared ABX464 for Phase 2b/3 “miR-AGE” testing
The anti-inflammatory mechanism of action could prevent and treat cytokine storm and hyper-inflammation, which lead to acute respiratory distress syndrome (ARDS) and death of COVID-19 patients
New data show ABX464 inhibits SARS-CoV-2 viral replication in vitro in a human respiratory epithelium model, making ABX464 a molecule with a potential triple action, antiviral, anti-inflammatory and tissue repair
50 French and European clinical trial sites to treat high-risk patients with complications early
Rigorous, randomized and placebo-controlled miR-AGE trial will include 1,034 patients with convenient oral administration
Discussions being finalized with Bpifrance and SGPI for ABX464 COVID-19 project grant funding
